Comparative Pharmacology
Head-to-head clinical analysis: PEDIAMYCIN 400 versus TAO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PEDIAMYCIN 400 versus TAO.
PEDIAMYCIN 400 vs TAO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin binds to the 50S subunit of the bacterial ribosome and inhibits protein synthesis by blocking the translocation step.
Troleandomycin (TAO) is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide chain elongation.
400 mg orally every 6 hours for 10 days.
250-500 mg orally every 6 hours or 500 mg intravenously every 6 hours. For severe infections, up to 500 mg every 6 hours IV.
None Documented
None Documented
1.5-2 hours; prolonged in renal impairment (up to 6 hours)
Terminal elimination half-life of 12-24 hours in adults; may be prolonged in hepatic impairment (up to 40-60 hours) and in neonates (2-5 days).
Renal (80-90% unchanged); biliary/fecal (minor, <5%)
Primarily hepatic metabolism with <10% excreted unchanged in urine; approximately 30% excreted in feces via bile.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic